Corcept Seeks FDA Approval for Relacorilant in Ovarian Cancer

• click to rate

  Posted by Two Blokes Jul 15 - Filed in Stock - 1 view
  
  CORT's relacorilant combo targets platinum-resistant ovarian cancer in new NDA, backed by positive ROSELLA study data.